Agilent Technologies, Inc.
A Healthcare Diagnostics & Research
Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024.
- Revenue
- +8.06%
- EPS
- +8.47%
- Free cash flow
- +69.5%
- Total debt
- +8.81%
Quarter to July 2026, against a year earlier
Follow A
Alert me
Agilent Technologies, Inc. (A) valuation and DCF model
At $175.70 the price implies free cash flow after share-based pay growing 16.6% a year for ten years.
Free cash flow after share-based pay grew 9.9% a year over the last ten years, 4.4% over the last five. The price asks for about twice its ten-year rate. The industry’s median company is priced for 15.8%.
In October 2017 the price assumed 13.2% a year; Agilent Technologies, Inc. went on to grow free cash flow after share-based pay 5.8% a year to FY2025.
- The price needs
- 16.6% a year for ten years
- $175.70
- today’s price
- Its base case
- 9.9% a year for five years, then 6.0%
- $90.22
- 48.7% below today’s price
Base case on its own ten-year record Agilent Technologies, Inc.’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$11.27b 10 years of cash to equity+$16.22b terminal value−$1.89b net debt=$25.60b equity value÷283.75m shares=$90.22 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 33.77× | 30.50× | 35.62× | 5% below | 34.52× | 2% below | |
| P/FCF | 38.20× | 32.62× | 32.15× | 19% above | 33.51× | 14% above | |
| P/B | 6.58× | 6.43× | 6.18× | 7% above | 3.42× | 93% above | |
| EV/EBITDA | 26.37× | 23.02× | 23.28× | 13% above | 23.44× | 12% above | |
| EV/Sales | 6.83× | 6.00× | 5.75× | 19% above | 5.18× | 32% above |
A trades at 6.58× P/B, against a 10-year average of 6.18× (range 4.53×–8.86×). That is dearer than 67% of the last 9 year-end readings; re-rating to the average implies $164.87 per share.